Article
LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
Hepatology (Baltimore, Md.) - 1 Nov 2025
Sun Rongqi, Liu Kaixuan, Pan Siyuan, Ye Yuhang, Li Ning, Chen Shuangyi, Cui Xinyi, Zhang Yuxi, Chen Long, Pan Jingyue, Hu Zhiqiang, Luo Chubin, Fan Jia, Zhou Zhengjun, Zhou Shaolai, Zhou Jian
Abstract excerpt
BACKGROUND AND AIMS: HCC recurrence is a major factor limiting long-term survival and the cause of most deaths in patients with HCC. However, molecular characterization and potential therapeutic targets of recurrent HCC remain mostly unknown. APPROACH AND RESULTS: We performed whole-exome sequencing in 63 matched primary and recurrent HCC tumors and combined the data with whole-genome sequencing results in 43...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Neoplasm Recurrence, Local
- Animals